Core Insights - ZetaDisplay has partnered with LG Electronics to enhance the deployment of digital signage content by preloading ZetaDisplay's Engage Suite software on LG's professional displays, aiming to simplify installation and accelerate content distribution [1][2] Company Overview - ZetaDisplay, founded in 2003 in Sweden, is a leading player in the digital signage market, with over 125,000 active installations across more than 50 countries [9][10] - The company has a turnover exceeding SEK 600 million and employs approximately 250 staff members [11] Product Features - Engage Suite is a modular digital signage software platform designed for secure, scalable, and reliable operation across various digital signage networks [3] - The platform includes a powerful content management system, an intuitive admin panel, and integrated apps for dynamic content and automation [3] - The preloaded Engage Suite significantly reduces setup complexity, allowing for immediate configuration after installation [4] Integration Benefits - The integration of Engage Suite allows organizations to deploy digital signage content more quickly and with fewer technical steps, transforming in-store screens into revenue-generating assets [2][6] - Built-in analytics and API integrations facilitate the management and scaling of retail media networks [6] Strategic Comments - ZetaDisplay's Chief Business Officer emphasized that seamless integration of software and hardware accelerates project timelines and simplifies rollouts [7] - LG Electronics' B2B Director highlighted the long-standing partnership with ZetaDisplay and the adaptability of Engage Suite to meet the unique challenges of the digital signage industry [7]

Group 1 - Borregaard ASA will report its fourth quarter 2025 results on February 4, 2026, at 07:00 CET, with a stock exchange announcement to follow [1] - A presentation of the results will take place at 08:30 CET at Pareto Securities AS in Oslo, and it will be available for live streaming on the company's website [2] - The presentations will be conducted in English, and attendees will have the opportunity to ask questions via the web [2] Group 2 - For further inquiries, Lotte Kvinlaug serves as the Investor Relations Officer and can be contacted at +47 922 86 909 [3] - The information provided is subject to the disclosure requirements under the Norwegian Securities Trading Act and the EU Market Abuse Regulation [3]

Core Viewpoint - Sampo plc has initiated a share buyback program, acquiring a total of 318,027 shares on 27 January 2026, as part of a broader plan to repurchase shares worth up to EUR 150 million, which commenced on 6 November 2025 [1][2]. Group 1: Share Buyback Details - On 27 January 2026, Sampo plc acquired 318,027 of its own A shares at an average price of EUR 9.43 per share across various markets [1]. - The buyback volume included 13,458 shares on AQEU, 123,778 shares on CEUX, 35,869 shares on TQEX, and 144,922 shares on XHEL [1]. - The share buyback program is in compliance with the Market Abuse Regulation (EU) 596/2014 and was authorized by Sampo's Annual General Meeting on 23 April 2025 [1]. Group 2: Ownership and Representation - Following the transactions, Sampo plc owns a total of 14,443,639 A shares, which represents 0.54% of the total number of shares in the company [2]. - The announcement of the buyback program and its details were communicated through various stock exchanges, including Nasdaq Helsinki, Nasdaq Stockholm, Nasdaq Copenhagen, and the London Stock Exchange [2].

Group 1 - The company reported FY25 Group service revenues increased by 2.7% year-on-year, with adjusted EBITDA AL of €2,636 million, reflecting a 5.1% year-on-year growth, including contributions of +1.0% from IPR and +1.0% from Althio [2] - Free cash flow (FCF) for FY25 was €952 million, with indirect costs reduced by €10 million year-on-year, indicating an improvement in operational performance [2] - In Q4, Group service revenue growth was 1.8% year-on-year, with all segments contributing positively [2] Group 2 - Consumer service revenues in Q4 rose by 1.2% year-on-year, supported by an improving trend in mobile service revenue [2] - The company experienced sustained commercial momentum in broadband, adding 12,000 net customers in Q4 and a record 38,000 for the full year [2] - Business service revenues increased by 2.3% year-on-year in Q4, primarily driven by small and medium enterprises (SME) [2] Group 3 - Wholesale service revenue grew by 3.9% year-on-year in Q4, mainly due to international sponsored roaming [2] - The company led the Dutch fiber market, adding 440,000 homes passed and 399,000 homes connected in FY25 [2] Group 4 - The outlook for 2026 includes service revenue growth of 2% to 2.5% year-on-year, adjusted EBITDA AL of approximately €2,670 million, capital expenditures around €1.25 billion, and free cash flow exceeding €950 million [2] - The company plans a 10% growth in dividends per share (€0.20 per share) and a new €250 million share buyback, returning all free cash flow to shareholders in 2026 [2]

Core Viewpoint - Idorsia Ltd has entered into an exclusive license and supply agreement with EMS S.A. to commercialize QUVIVIQ™ (daridorexant) in Latin America, marking a significant step in the company's global expansion strategy [2][3]. Company Overview - Idorsia is focused on developing transformative medicines and aims to challenge existing medical paradigms. The company is headquartered in Allschwil, Switzerland, and is listed on the SIX Swiss Exchange [15][16]. - EMS S.A. is Brazil's largest privately-owned pharmaceutical company, with over 60 years of history and a strong market presence in various pharmaceutical segments [13][14]. Product Information - QUVIVIQ is an innovative treatment for insomnia that selectively blocks orexin receptors, promoting restorative sleep without broadly suppressing brain activity. It is designed to improve both sleep quality and daytime functioning [5][6]. - Clinical trials have shown that daridorexant significantly improves sleep onset, maintenance, and total sleep time, with a notable enhancement in daytime functioning at a 50 mg dose compared to placebo [6]. Market Potential - Insomnia affects millions in Latin America, with current treatments often leading to next-day drowsiness and dependence, indicating a strong unmet need for safer alternatives [4][11]. - The partnership with EMS is expected to enhance the availability of QUVIVIQ in Latin America, reinforcing Idorsia's commitment to making the product a global brand [7][10]. Financial Terms - Idorsia is set to receive a total milestone compensation of USD 20 million for the execution of the agreement, along with supply prices and double-digit royalties on net sales in Brazil and Mexico [10].

Core Viewpoint - Discovery Silver Corp. is set to release its financial and operating results for Q4 and the full year 2025 on February 19, 2026, before market opening, followed by a conference call to discuss the results [1]. Group 1: Financial Results Announcement - The financial and operating results will be released prior to market open on February 19, 2026 [1]. - A conference call to review the results will take place at 2:00 pm ET on the same day [1]. Group 2: Company Overview - Discovery Silver Corp. is a growing precious metals company focused on gold and silver, with significant exposure through its Cordero project, one of the largest undeveloped silver deposits globally [2]. - The acquisition of the Porcupine Complex on April 15, 2025, has positioned the company as a new Canadian gold producer with multiple operations in a renowned gold camp near Timmins, Ontario [2]. - The company holds a dominant land position within the Timmins gold camp, with substantial mineral resources and exploration potential [2].

Core Insights - Canada Carbon Inc. has completed a third drilling campaign at its Asbury Graphite Property, enhancing its resource evaluation and de-risking efforts [1][4] - The drilling program, which took place from November 4 to December 10, 2025, achieved 2,517 meters of drilling out of a planned 5,200 meters, contributing to a total of over 7,500 meters of core samples from previous campaigns [2][4] - The company aims to update its NI 43-101 resource report and complete a pre-feasibility study by June 30, 2026, following its maiden resource estimate of 4.14 million tons with an average grade of 3.05% Cg [4] Drilling Campaign Details - The recent drilling campaign focused on the Northeast and Southwest portions of the Asbury property, which is located near Notre-Dame-du-Laus, Quebec [1] - Historical data indicates that Asbury was an operational graphite mine from 1974 to 1988, producing high-quality concentrate [4] - The results from the Fall 2023 drilling campaign included significant graphite grades, such as 12.25% Cg over 22.50 meters [8] Future Plans and Expectations - The company is optimistic about the commercial potential of the Asbury project and its contribution to the local economy and Quebec's strategic mineral development efforts [4] - Canada Carbon is committed to maintaining high standards of social and environmental responsibility while developing its graphite deposits [13]

Core Viewpoint - Altimmune, Inc. has entered into a securities purchase agreement for the sale of 17,045,454 shares of common stock, expected to generate approximately $75 million in gross proceeds, to fund its Phase 3 trial for pemvidutide and for general corporate purposes [1][2]. Group 1: Offering Details - The offering involves 17,045,454 shares of common stock or pre-funded warrants, with gross proceeds anticipated to be around $75 million before expenses [1]. - The offering is expected to close on or about January 29, 2026, pending customary closing conditions [1]. - Titan Partners is acting as the sole placement agent for this offering [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to prepare for the upcoming Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH), along with working capital and general corporate purposes [2]. - Pemvidutide is a dual agonist targeting glucagon and GLP-1 receptors, showing potential as a differentiated therapy for MASH, supported by recent Phase 2b data and Breakthrough Therapy Designation from the U.S. FDA [2]. Group 3: Company Overview - Altimmune is a late clinical-stage biopharmaceutical company focused on therapies for serious liver diseases, with pemvidutide as its lead candidate [6]. - The company aims to deliver significant patient impact and long-term shareholder value through its innovative therapies [2].

Core Viewpoint - Osisko Development Corp. has successfully completed the sale of its 100% interest in the San Antonio Gold Project to Axo Copper Corp., marking a significant transaction for the company [1]. Group 1: Transaction Details - Osisko Development received 15,325,841 common shares of Axo, representing 9.99% of Axo's issued and outstanding common shares on a non-diluted basis at the closing of the transaction [2]. - The company is entitled to contingent deferred payments, including a cash payment equal to 70% of any Mexican value-added tax refund due to Sapuchi Mexico, and a payment of US$2,000,000 upon the public filing of a feasibility study by Axo [6]. - If Axo raises at least US$10,000,000 in equity financing, Osisko Development will retain a 9.99% interest in Axo, with specific conditions based on the issue price of the shares [2][6]. Group 2: Company Overview - Osisko Development Corp. is focused on developing past-producing mining camps with district-scale potential, aiming to become an intermediate gold producer through its flagship Cariboo Gold Project in British Columbia, Canada [4]. - The company also has a project pipeline that includes the Tintic Project in Utah, which has significant exploration potential and access to established infrastructure [4]. - Osisko Development emphasizes a disciplined approach to capital allocation, development risk management, and mineral inventory growth in mining-friendly jurisdictions [4].

Core Insights - WeRide has launched WeRide GENESIS, a proprietary general-purpose simulation model that integrates physical AI and generative AI to enhance the development and validation of autonomous vehicles at scale [1][20]. Group 1: Technology and Features - WeRide GENESIS utilizes generative AI to create highly realistic virtual environments, enabling rapid simulation of complex driving scenarios that are challenging to replicate in real-world testing [2][4]. - The platform includes four core AI modules: AI Scenarios, AI Agents, AI Metrics, and AI Diagnosis, which collectively enhance the training and validation processes for autonomous driving algorithms [6][18]. - The AI Scenarios module simulates a wide range of driving situations, including rare and extreme events, using billions of kilometers of real-world driving data to prepare AVs for complex edge cases [8][9]. Group 2: Benefits and Efficiency - The simulation platform allows for large-scale training and validation of AVs, significantly improving efficiency and reducing costs compared to traditional road testing methods [2][5]. - WeRide GENESIS provides a closed-loop optimization framework that continuously feeds performance insights back into real-world operations, enhancing safety and reliability [13][18]. - The AI Metrics and AI Diagnosis modules automate performance evaluation and root-cause analysis, enabling real-time feedback for algorithm improvements [14][15]. Group 3: Global Impact and Market Position - WeRide GENESIS is designed to accommodate diverse urban conditions and vehicle types, allowing for a unified training platform that optimizes R&D resources and accelerates deployment [16][21]. - The company holds autonomous driving permits in eight countries and operates AVs in over 40 cities, establishing a leading position in global commercial deployments [17][21]. - The launch of WeRide GENESIS represents a significant advancement in the application of physical AI, positioning the company as a leader in the autonomous driving simulation industry [20].